Quarter
Charts

DEXCOM, INC.

DXCM

CIK 0001093557 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$1.19B
↑+15.0% +$156Mvs FY2025 (Q1)
Operating Income
$255M
↑+90.9% +$122Mvs FY2025 (Q1)
Net Income
$200M
↑+89.3% +$94Mvs FY2025 (Q1)
Gross Profit
$750M
↑+27.4% +$161Mvs FY2025 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
79/100
  • Profitability
    100ROIC 28.9% (10% = solid, 20%+ = moat)
  • Liquidity
    69Current Ratio 1.88 (above 1.5 = solid)
  • Leverage
    98D/E 0.03 (under 0.5 = conservative)
  • Efficiency
    41Asset Turnover 0.73x (1.0+ = capital-efficient)
  • Growth
    67Revenue YoY +15.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 21.4% · trend +6.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project DXCM's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 52.3%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$88.61
Total enterprise IV
$35.93B
Diluted shares
0.41B
Terminal PV
$27.90B (78% of total)
Year-5 FCF
$3.29B
YearProjected FCFDiscounted PV
+1$1.35B$1.22B
+2$1.68B$1.39B
+3$2.10B$1.58B
+4$2.63B$1.80B
+5$3.29B$2.04B
Terminal$44.93B$27.90B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$353M
investment in PP&E
Stock buybacks (TTM)
$313M
share count reduction
Stock-based comp (TTM)
$169M
non-cash dilution

Balance sheet · 2026-03-31

latest filed snapshot
Total assets
$6.63B
everything owned
Total liabilities
$3.68B
everything owed
Stockholders' equity
$2.96B
shareholder claim
Net debt
$-1.12B
Net cash position ($1.12B)

Recent performance · 66 quarters

Revenue↑+15.0% +$156M
$1.19B
Net Income↑+89.3% +$94M
$200M
Free Cash Flow↑+363.8% +$352M
$449M
Operating Margin↑+8.5pts
21.4%

Drill down

DXCM Sankey

See DEXCOM, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

DXCM Charts

66 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

DXCM Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics